Regulation of Adaptive Tumor Immunity by Non-Coding RNAs
Abstract
:Simple Summary
Abstract
1. Introduction
2. Non-Coding RNAs as Regulators of Gene Expression
2.1. Non-Coding RNAs
2.2. MicroRNAs
2.3. Long Non-Coding RNAs
3. Regulation of Adaptive Tumor Immunity by Non-Coding RNAs
3.1. Immune Responses in Cancer
3.2. Non-Coding RNAs in Immune Responses to Cancer
4. Conclusions and Future Prospects
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today 2021; International Agency for Research on Cancer: Lyon, France, 2021. [Google Scholar]
- Hanahan, D.; Weinberg, R.A. The Hallmarks of Cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef] [Green Version]
- Tran, E.; Turcotte, S.; Gros, A.; Robbins, P.F.; Lu, Y.-C.; Dudley, M.E.; Wunderlich, J.R.; Somerville, R.P.; Hogan, K.; Hinrichs, C.S.; et al. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer. Science 2014, 344, 641–645. [Google Scholar] [CrossRef]
- Robbins, P.F.; Lu, Y.C.; El-Gamil, M.; Li, Y.F.; Gross, C.; Gartner, J.; Lin, J.C.; Teer, J.K.; Cliften, P.; Tycksen, E.; et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19, 747–752. [Google Scholar] [CrossRef] [PubMed]
- Linnemann, C.; Van Buuren, M.M.; Bies, L.; Verdegaal, E.M.E.; Schotte, R.; Calis, J.J.A.; Behjati, S.; Velds, A.; Hilkmann, H.; El Atmioui, D.; et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 2015, 21, 81–85. [Google Scholar] [CrossRef] [PubMed]
- Coulie, P.G.; Van den Eynde, B.J.; Van Der Bruggen, P.; Boon-Falleur, T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat. Rev. Cancer 2014, 14, 135–146. [Google Scholar] [CrossRef] [PubMed]
- Verdegaal, E.M.E.; de Miranda, N.F.C.C.; Visser, M.; Harryvan, T.; van Buuren, M.M.; Andersen, R.S.; Hadrup, S.R.; van der Minne, C.E.; Schotte, R.; Spits, H.; et al. Neoantigen landscape dynamics during human melanoma–T cell interactions. Nat. Cell Biol. 2016, 536, 91–95. [Google Scholar] [CrossRef] [PubMed]
- Dunn, G.P.; Old, L.J.; Schreiber, R.D. The Three Es of Cancer Immunoediting. Annu. Rev. Immunol. 2004, 22, 329–360. [Google Scholar] [CrossRef]
- Bhatia, S.; Thompson, J.A. PD-1 Blockade in Melanoma. JAMA 2016, 315, 1573–1575. [Google Scholar] [CrossRef] [PubMed]
- Thomas, D.A.; Massagué, J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005, 8, 369–380. [Google Scholar] [CrossRef] [Green Version]
- Schietinger, A.; Greenberg, P.D. Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. Trends Immunol. 2014, 35, 51–60. [Google Scholar] [CrossRef] [Green Version]
- Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of Antitumor Immunity by CTLA-4 Blockade. Science 1996, 271, 1734–1736. [Google Scholar] [CrossRef] [Green Version]
- Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell 2015, 27, 450–461. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.; Leitman, S.; Chang, A.E.; Ettinghausen, S.E.; Matory, Y.L.; Skibber, J.M.; Shiloni, E.; Vetto, J.T.; et al. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer. N. Engl. J. Med. 1985, 313, 1485–1492. [Google Scholar] [CrossRef] [PubMed]
- Salles, G.; Barrett, M.; Foà, R.; Maurer, J.; O’Brien, S.; Valente, N.; Wenger, M.; Maloney, D.G. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv. Ther. 2017, 34, 2232–2273. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tawbi, H.A.; Forsyth, P.A.; Algazi, A.; Hamid, O.; Hodi, F.S.; Moschos, S.J.; Khushalani, N.I.; Lewis, K.; Lao, C.D.; Postow, M.A.; et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N. Engl. J. Med. 2018, 379, 722–730. [Google Scholar] [CrossRef]
- Postow, M.A.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwala, S.S.; et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N. Engl. J. Med. 2015, 372, 2006–2017. [Google Scholar] [CrossRef] [Green Version]
- Mondal, M.; Guo, J.; He, P.; Zhou, D. Recent advances of oncolytic virus in cancer therapy. Hum. Vaccines Immunother. 2020, 16, 2389–2402. [Google Scholar] [CrossRef]
- Pan, J.; Niu, Q.; Deng, B.; Liu, S.; Wu, T.; Gao, Z.; Liu, Z.; Zhang, Y.; Qu, X.; Zhang, Y.; et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 2019, 33, 2854–2866. [Google Scholar] [CrossRef] [Green Version]
- Sharma, P.; Hu-Lieskovan, S.; Wargo, J.A.; Ribas, A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 2017, 168, 707–723. [Google Scholar] [CrossRef] [Green Version]
- Maude, S.L.; Frey, N.; Shaw, P.A.; Aplenc, R.; Barrett, D.M.; Bunin, N.J.; Chew, A.; Gonzalez, V.E.; Zheng, Z.; Lacey, S.F.; et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 2014, 371, 1507–1517. [Google Scholar] [CrossRef] [Green Version]
- Zhang, E.; Gu, J.; Xu, H. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Mol. Cancer 2018, 17, 7. [Google Scholar] [CrossRef] [Green Version]
- June, C.H.; Warshauer, J.T.; Bluestone, J.A. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat. Med. 2017, 23, 540–547. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Caspi, R.R. Immunotherapy of autoimmunity and cancer: The penalty for success. Nat. Rev. Immunol. 2008, 8, 970–976. [Google Scholar] [CrossRef] [PubMed]
- Djebali, S.; Davis, C.A.; Merkel, A.; Dobin, A.; Lassmann, T.; Mortazavi, A.; Tanzer, A.; Lagarde, J.; Lin, W.; Schlesinger, F.; et al. Landscape of transcription in human cells. Nature 2012, 489, 101–108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chi, Y.; Wang, J.; Yu, W.; Yang, J. Long Non-Coding RNA in the Pathogenesis of Cancers. Cells 2019, 8, 1015. [Google Scholar] [CrossRef] [Green Version]
- Li, J.; Sun, D.; Pu, W.; Wang, J.; Peng, Y. Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance. Trends Cancer 2020, 6, 319–336. [Google Scholar] [CrossRef]
- Zhang, B.; Pan, X.; Cobb, G.; Anderson, T. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302, 1–12. [Google Scholar] [CrossRef] [Green Version]
- Cobb, B.S.; Nesterova, T.; Thompson, E.; Hertweck, A.; O’Connor, E.; Godwin, J.; Wilson, C.B.; Brockdorff, N.; Fisher, A.G.; Smale, S.T.; et al. T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J. Exp. Med. 2005, 201, 1367–1373. [Google Scholar] [CrossRef] [Green Version]
- Koralov, S.; Muljo, S.; Galler, G.; Krek, A.; Chakraborty, T.; Kanellopoulou, C.; Jensen, K.; Cobb, B.S.; Merkenschlager, M.; Rajewsky, K. Dicer Ablation Affects Antibody Diversity and Cell Survival in the B Lymphocyte Lineage. Cell 2008, 132, 860–874. [Google Scholar] [CrossRef] [Green Version]
- Casero, D.; Sandoval, S.; Seet, C.S.; Scholes, J.; Zhu, Y.; Ha, V.L.; Luong, A.; Parekh, C.; Crooks, G.M. Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. Nat. Immunol. 2015, 16, 1282–1291. [Google Scholar] [CrossRef]
- Kosaka, A.; Ohkuri, T.; Ikeura, M.; Kohanbash, G.; Okada, H. Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochem. Biophys. Res. Commun. 2015, 458, 549–554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jathar, S.; Kumar, V.; Srivastava, J.; Tripathi, V. Technological Developments in lncRNA Biology. Adv. Exp. Med. Biol. 2017, 1008, 283–323. [Google Scholar] [PubMed]
- Hombach, S.; Kretz, M. Non-coding RNAs: Classification, Biology and Functioning. Adv. Exp. Med. Biol. 2016, 937, 3–17. [Google Scholar] [CrossRef]
- Huang, B.; Zhang, R. Regulatory non-coding RNAs: Revolutionizing the RNA world. Mol. Biol. Rep. 2014, 41, 3915–3923. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.G.; Satpathy, A.; Chang, H.Y. Gene regulation in the immune system by long noncoding RNAs. Nat. Immunol. 2017, 18, 962–972. [Google Scholar] [CrossRef] [PubMed]
- Bartel, D.P. MicroRNAs: Target Recognition and Regulatory Functions. Cell 2009, 136, 215–233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huntzinger, E.; Izaurralde, E. Gene silencing by microRNAs: Contributions of translational repression and mRNA decay. Nat. Rev. Genet. 2011, 12, 99–110. [Google Scholar] [CrossRef] [PubMed]
- Mehta, A.; Baltimore, D. MicroRNAs as regulatory elements in immune system logic. Nat. Rev. Immunol. 2016, 16, 279–294. [Google Scholar] [CrossRef]
- Zhang, P.; Wu, W.; Chen, Q.; Chen, M. Non-Coding RNAs and their Integrated Networks. J. Integr. Bioinform. 2019, 16, 3. [Google Scholar] [CrossRef]
- Xiao, C.; Rajewsky, K. MicroRNA Control in the Immune System: Basic Principles. Cell 2009, 136, 26–36. [Google Scholar] [CrossRef] [Green Version]
- Lai, M.; Gonzalez-Martin, A.; Cooper, A.B.; Oda, H.; Jin, H.Y.; Shepherd, J.; He, L.; Zhu, J.; Nemazee, D.; Xiao, C. Regulation of B-cell development and tolerance by different members of the miR-17∼92 family microRNAs. Nat. Commun. 2016, 7, 12207. [Google Scholar] [CrossRef] [Green Version]
- Rinn, J.L.; Chang, H.Y. Genome Regulation by Long Noncoding RNAs. Annu. Rev. Biochem. 2012, 81, 145–166. [Google Scholar] [CrossRef] [Green Version]
- Iyer, M.K.; Niknafs, Y.; Malik, R.; Malik, R.; Singhal, U.; Sahu, A.; Hosono, Y.; Barrette, T.R.; Prensner, J.R.; Evans, J.R.; et al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet. 2015, 47, 199–208. [Google Scholar] [CrossRef] [PubMed]
- Yang, J.X.; Rastetter, R.H.; Wilhelm, D. Non-coding RNAs: An Introduction. Adv. Exp. Med. Biol. 2016, 886, 13–32. [Google Scholar] [PubMed]
- Mercer, T.R.; Dinger, M.E.; Mattick, J.S. Long non-coding RNAs: Insights into functions. Nat. Rev. Genet. 2009, 10, 155–159. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.-L.; Yang, L. Regulation of circRNA biogenesis. RNA Biol. 2015, 12, 381–388. [Google Scholar] [CrossRef]
- Kristensen, L.S.; Andersen, M.S.; Stagsted, L.V.W.; Ebbesen, K.K.; Hansen, T.B.; Kjems, J. The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 2019, 20, 675–691. [Google Scholar] [CrossRef]
- Coussens, L.M.; Werb, Z. Inflammatory Cells and Cancer. J. Exp. Med. 2001, 193, F23–F26. [Google Scholar] [CrossRef]
- Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [Google Scholar] [CrossRef]
- Ghiringhelli, F.; Apetoh, L.; Housseau, F.; Kroemer, G.; Zitvogel, L. Links between innate and cognate tumor immunity. Curr. Opin. Immunol. 2007, 19, 224–231. [Google Scholar] [CrossRef]
- Zhu, J.; Yamane, H.; Paul, W.E. Differentiation of Effector CD4 T Cell Populations. Annu. Rev. Immunol. 2010, 28, 445–489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stout, R.D.; Bottomly, K. Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages. J. Immunol. 1989, 142, 760–765. [Google Scholar] [PubMed]
- Martinez, F.O. Macrophage activation and polarization. Front. Biosci. 2008, 13, 453–461. [Google Scholar] [CrossRef] [Green Version]
- DeNardo, D.G.; Coussens, L.M. Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007, 9, 212. [Google Scholar] [CrossRef] [PubMed]
- David, H. Rudolf Virchow and Modern Aspects of Tumor Pathology. Pathol.-Res. Pract. 1988, 183, 356–364. [Google Scholar] [CrossRef]
- Grivennikov, S.I.; Greten, F.; Karin, M. Immunity, Inflammation, and Cancer. Cell 2010, 140, 883–899. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nallasamy, P.; Chava, S.; Verma, S.S.; Mishra, S.; Gorantla, S.; Coulter, D.W.; Byrareddy, S.N.; Batra, S.K.; Gupta, S.C.; Challagundla, K.B. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. Semin. Cancer Biol. 2018, 52, 53–65. [Google Scholar] [CrossRef]
- Sharpe, A.H. Introduction to checkpoint inhibitors and cancer immunotherapy. Immunol. Rev. 2017, 276, 5–8. [Google Scholar] [CrossRef] [Green Version]
- Bronte, V.; Serafini, P.; Apolloni, E.; Zanovello, P. Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells. J. Immunother. 2001, 24, 431–446. [Google Scholar] [CrossRef]
- Gallina, G.; Dolcetti, L.; Serafini, P.; De Santo, C.; Marigo, I.; Colombo, M.P.; Basso, G.; Brombacher, F.; Borrello, I.; Zanovello, P.; et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Investig. 2006, 116, 2777–2790. [Google Scholar] [CrossRef]
- Leidinger, P.; Backes, C.; Dahmke, I.N.; Galata, V.; Huwer, H.; Stehle, I.; Bals, R.; Keller, A.; Meese, E. What makes a blood cell based miRNA expression pattern disease specific?—A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls. Oncotarget 2014, 5, 9484–9497. [Google Scholar] [CrossRef] [Green Version]
- Zhong, G.; Cheng, X.; Long, H.; He, L.; Qi, W.; Xiang, T.; Zhao, Z.; Zhu, B. Dynamically expressed microRNA-15b modulates the activities of CD8+ T lymphocytes in mice with Lewis lung carcinoma. J. Transl. Med. 2013, 11, 71. [Google Scholar] [CrossRef] [Green Version]
- Lin, R.; Chen, L.; Chen, G.; Hu, C.; Jiang, S.; Sevilla, J.; Wan, Y.; Sampson, J.; Zhu, B.; Li, Q.-J. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression. J. Clin. Investig. 2014, 124, 5352–5367. [Google Scholar] [CrossRef]
- Fabbri, M.; Paone, A.; Calore, F.; Galli, R.; Gaudio, E.; Santhanam, R.; Lovat, F.; Fadda, P.; Mao, C.; Nuovo, G.J.; et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA 2012, 109, E2110–E2116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, T.; Zuo, Q.-F.; Gong, L.; Wang, L.-N.; Zou, Q.-M.; Xiao, B. MicroRNA-491 regulates the proliferation and apoptosis of CD8+ T cells. Sci. Rep. 2016, 6, 30923. [Google Scholar] [CrossRef] [PubMed]
- Garo, L.P.; Ajay, A.K.; Fujiwara, M.; Gabriely, G.; Raheja, R.; Kuhn, C.; Kenyon, B.; Skillin, N.; Kadowaki-Saga, R.; Saxena, S.; et al. MicroRNA-146a limits tumorigenic inflammation in colorectal cancer. Nat. Commun. 2021, 12, 2419. [Google Scholar] [CrossRef] [PubMed]
- Mao, D.; Hu, C.; Zhang, J.; Feng, C.; Zhang, Z.; Wang, J.; Man, Z.; Zhu, Z.; Wang, Y.; Zhao, H.; et al. Long Noncoding RNA GM16343 Promotes IL-36β to Regulate Tumor Microenvironment by CD8+T cells. Technol. Cancer Res. Treat. 2019, 18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- He, W.; Wang, C.; Mu, R.; Liang, P.; Huang, Z.; Zhang, J.; Dong, L. MiR-21 is required for anti-tumor immune response in mice: An implication for its bi-directional roles. Oncogene 2017, 36, 4212–4223. [Google Scholar] [CrossRef]
- Yan, K.; Fu, Y.; Zhu, N.; Wang, Z.; Hong, J.-L.; Li, Y.; Li, W.-J.; Zhang, H.-B.; Song, J.-H. Repression of lncRNA NEAT1 enhances the antitumor activity of CD8+T cells against hepatocellular carcinoma via regulating miR-155/Tim-3. Int. J. Biochem. Cell Biol. 2019, 110, 1–8. [Google Scholar] [CrossRef]
- Ji, J.; Yin, Y.; Ju, H.; Xu, X.; Liu, W.; Fu, Q.; Hu, J.; Zhang, X.; Sun, B. Long non-coding RNA Lnc-Tim3 exacerbates CD8 T cell exhaustion via binding to Tim-3 and inducing nuclear translocation of Bat3 in HCC. Cell Death Dis. 2018, 9, 478. [Google Scholar] [CrossRef]
- Martinez-Usatorre, A.; Sempere, L.F.; Carmona, S.J.; Carretero-Iglesia, L.; Monnot, G.; Speiser, D.E.; Rufer, N.; Donda, A.; Zehn, D.; Jandus, C.; et al. MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma. Cancer Immunol. Res. 2019, 7, 1013–1024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dudda, J.C.; Salaun, B.; Ji, Y.; Palmer, D.C.; Monnot, G.C.; Merck, E.; Boudousquie, C.; Utzschneider, D.T.; Escobar, T.M.; Perret, R.; et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 2013, 38, 742–753. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huffaker, T.B.; Hu, R.; Runtsch, M.C.; Bake, E.; Chen, X.; Zhao, J.; Round, J.L.; Baltimore, D.; O’Connell, R.M. Epistasis between MicroRNAs 155 and 146a during T Cell-Mediated Antitumor Immunity. Cell Rep. 2012, 2, 1697–1709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ji, Y.; Wrzesinski, C.; Yu, Z.; Hu, J.; Gautam, S.; Hawk, N.V.; Telford, W.G.; Palmer, D.; Franco, Z.; Sukumar, M.; et al. miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γc cytokines. Proc. Natl. Acad. Sci. USA 2015, 112, 476–481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jiang, S.; Li, C.; Olive, V.; Lykken, E.; Feng, F.; Sevilla, J.; Wan, Y.; He, L.; Li, Q.-J. Molecular dissection of the miR-17-92 cluster’s critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation. Blood 2011, 118, 5487–5497. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Johnston, N.; Zheng, X.; Wang, H.; Zhang, X.; Gao, D.; Min, W. miR-28 modulates exhaustive differentiation of T cells through silencing programmed cell death-1 and regulating cytokine secretion. Oncotarget 2016, 7, 53735–53750. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, M.; Gao, D.; Shi, Y.; Wang, Y.; Joshi, R.; Yu, Q.; Liu, D.; Alotaibi, F.; Zhang, Y.; Wang, H.; et al. miR-149-3p reverses CD8 + T-cell exhaustion by reducing inhibitory receptors and promoting cytokine secretion in breast cancer cells. Open Biol. 2019, 9, 190061. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wei, J.; Wang, F.; Kong, L.-Y.; Xu, S.; Doucette, T.; Ferguson, S.D.; Yang, Y.; McEnery, K.; Jethwa, K.; Gjyshi, O.; et al. miR-124 Inhibits STAT3 Signaling to Enhance T Cell–Mediated Immune Clearance of Glioma. Cancer Res. 2013, 73, 3913–3926. [Google Scholar] [CrossRef] [Green Version]
- Wei, J.; Nduom, E.K.; Kong, L.-Y.; Hashimoto, Y.; Xu, S.; Gabrusiewicz, K.; Ling, X.; Huang, N.; Qiao, W.; Zhou, S.; et al. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology 2016, 18, 639–648. [Google Scholar] [CrossRef] [Green Version]
- Murugaiyan, G.; Beynon, V.; Mittal, A.; Joller, N.; Weiner, H.L. Silencing MicroRNA-155 Ameliorates Experimental Autoimmune Encephalomyelitis. J. Immunol. 2011, 187, 2213–2221. [Google Scholar] [CrossRef] [Green Version]
- Garchow, B.G.; Encinas, O.B.; Leung, Y.T.; Tsao, P.Y.; Eisenberg, R.A.; Caricchio, R.; Obad, S.; Petri, A.; Kauppinen, S.; Kiriakidou, M. Silencing of microRNA-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol. Med. 2011, 3, 605–615. [Google Scholar] [CrossRef] [PubMed]
- Mattes, J.; Collison, A.; Plank, M.; Phipps, S.; Foster, P.S. Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease. Proc. Natl. Acad. Sci. USA 2009, 106, 18704–18709. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Li, Y.; Zhang, P.; Baker, S.T.; Wolfson, M.R.; Weiser, J.; Tian, Y.; Shen, H. Regenerative therapy based on miRNA-302 mimics for enhancing host recovery from pneumonia caused byStreptococcus pneumoniae. Proc. Natl. Acad. Sci. USA 2019, 116, 8493–8498. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.-H.; Hsu, K.-W.; Lai, Y.-L.; Lin, Y.-F.; Chen, F.-H.; Peng, P.-H.; Lin, L.-J.; Wu, H.-H.; Li, C.-Y.; Wang, S.-C.; et al. Systematic identification of clinically relevant miRNAs for potential miRNA-based therapy in lung adenocarcinoma. Mol. Ther.-Nucleic Acids 2021, 25, 1–10. [Google Scholar] [CrossRef] [PubMed]
- Murugaiyan, G.; Da Cunha, A.P.; Ajay, A.K.; Joller, N.; Garo, L.P.; Kumaradevan, S.; Yosef, N.; Vaidya, V.S.; Weiner, H.L. MicroRNA-21 promotes Th17 differentiation and mediates experimental autoimmune encephalomyelitis. J. Clin. Investig. 2015, 125, 1069–1080. [Google Scholar] [CrossRef] [PubMed]
- Janssen, H.L.A.; Reesink, H.W.; Lawitz, E.J.; Zeuzem, S.; Rodriguez-Torres, M.; Patel, K.; Van Der Meer, A.J.; Patick, A.K.; Chen, A.; Zhou, Y.; et al. Treatment of HCV Infection by Targeting MicroRNA. N. Engl. J. Med. 2013, 368, 1685–1694. [Google Scholar] [CrossRef] [Green Version]
- ClinicalTrials.gov. 2021. Available online: https://clinicaltrials.gov/ (accessed on 9 September 2021).
ncRNA | Cell Subset | Function | Cancer | References |
---|---|---|---|---|
miR-15b | CD8 T cells | ↓ AICD ↓ IFN-γ/IL-2 production | Lung | [63] |
miR-23a | CD8 T cells | ↓ Cytotoxicity ↓ IFN-γ production ↓ Blimp-1, Eomes, T-bet, Granzyme B | Lung Melanoma | [64] |
miR-146a | T cells | ↓ Antitumor responses ↓ IFN-γ production | Melanoma | [74] |
miR-491 | T cells | ↓ Proliferation ↓ IFN-γ production ↑ Apoptosis ↓ Bcl-xL, TCF-1, CDK4 | Colorectal | [66] |
Lnc NEAT1 | CD8 T cells | ↓ Cytotoxicity ↑ Tim3 | Hepatocarcinoma | [70] |
Lnc-Tim3 | CD8 T cells | ↑ Exhaustion ↓ IL-2/IFN-γ production Binds Tim-3 and blocks interaction with Bat3 | Hepatocarcinoma | [71] |
miR-17-92 | T cells | ↑ Th1 function ↑ CD4 T cell help to CD8 T cells ↓ iTreg induction ↓ Pten, TGFRII, CREB1 | Melanoma | [76] |
miR-21 | T cells | ↑ Antitumor responses ↑ Proliferation ↑ IFN-γ/IL-2 production ↓ Pten signaling | Hepatoma Fibrosarcoma | [69] |
miR-28 | T cells | ↓ Exhaustion ↑ IL-2/TNF-α production | Melanoma | [77] |
miR-124 | T cells | ↑ Proliferation ↓ Treg induction ↑ IFN-γ/IL-2/TNF-α production ↓ STAT3 | Glioma | [79] |
miR-138 | T cells | ↓ Treg induction ↓ CTLA-4, PD-1 | Glioma | [80] |
miR-146a | CD4 T cells | ↓ IL-17 production | Colorectal | [67] |
miR-149-3p | CD8 T cells | ↓ Exhaustion ↑ Activation ↑ Cytotoxicity ↑ IFN-γ/IL-2/TNF-α production | Breast | [78] |
miR-155 | T cells | ↑ Antitumor responses ↑ IFN-γ production ↓ Ship1 | Melanoma Thymic lymphoma | [72,73,74,75] |
Lnc GM16343 | CD8 T cells | ↑ IFN-γ production | Colon | [68] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Papaioannou, E.; González-Molina, M.d.P.; Prieto-Muñoz, A.M.; Gámez-Reche, L.; González-Martín, A. Regulation of Adaptive Tumor Immunity by Non-Coding RNAs. Cancers 2021, 13, 5651. https://doi.org/10.3390/cancers13225651
Papaioannou E, González-Molina MdP, Prieto-Muñoz AM, Gámez-Reche L, González-Martín A. Regulation of Adaptive Tumor Immunity by Non-Coding RNAs. Cancers. 2021; 13(22):5651. https://doi.org/10.3390/cancers13225651
Chicago/Turabian StylePapaioannou, Eleftheria, María del Pilar González-Molina, Ana M. Prieto-Muñoz, Laura Gámez-Reche, and Alicia González-Martín. 2021. "Regulation of Adaptive Tumor Immunity by Non-Coding RNAs" Cancers 13, no. 22: 5651. https://doi.org/10.3390/cancers13225651